



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Keith D. ALLEN

Group Art Unit: 1636

Serial No.: 09/900,708

Examiner: Qian, Celine X.

Filed: July 6, 2001

Attorney Docket No.: R-733

For: TRANSGENIC MICE CONTAINING INTESTINAL ALKALINE PHOSPHATASE
GENE DISRUPTIONS

TECH CENTER 1600/2900

FEB 10 2003

RECEIVED

11/12/03

Taka
R-B

AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated August 26, 2002, in connection with the above-identified application, Applicant respectfully requests entry and consideration of the following amendments and remarks. The Applicant submits concurrently herewith a Petition for Extension of Time for a period of two months from November 26, 2002 up to and including January 26, 2003.

THE AMENDMENTS

In the Claims:

Please cancel claims 1-10 and 17-28.

Please add new claims 35-46 as follows:

35. (New) A transgenic mouse comprising a disruption in an endogenous intestinal alkaline phosphatase gene, wherein where the disruption is homozygous, the transgenic mouse exhibits, relative to a wild-type mouse, a nociceptive abnormality or abnormal activity level.

36. (New) The transgenic mouse of claim 35, wherein the nociceptive abnormality comprises an increased sensitivity to pain.



10368

PTO/SB/21 (07/00)
Approved for use through 04/30/2003 OMB 0651-0002
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

RECEIVED
FEB 10 2003
RECEIVED CENTER 1600/2900

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/900,708
	Filing Date	July 6, 2001
	First Named Inventor	KEITH D. ALLEN
	Art Unit	1636
	Examiner Name	Qian, Celine X.
Total Number of Pages in This Submission	Attorney Docket Number	R-733

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Aaron T. Hokamura, Reg. No. 51,810
Signature	<i>Aaron Hokamura</i>
Date	January 27, 2003

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: January 27, 2003			
Typed or printed	Donald Mixon		
Signature	<i>Donald Mixon</i>	Date	January 27, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/17 (01-03)
Approved for use through 04/30/2003. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 205.00

Complete if Known

Application Number 09/900,708
Filing Date July 6, 2001
First Named Inventor KEITH D. ALLEN
Examiner Name Qian, Celine X.
Art Unit 1636
Attorney Docket No. R-733

RECEIVED
FEB 10 2003
TECH CENTER 1636/2600

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number 50-1271

Deposit Account Name Deltagen, Inc.

The Commissioner is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☐ Credit any overpayments

☐ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	750	2001	375	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims		Fee from below	Fee Paid
Total Claims	<input type="text"/>	-20** =	<input type="text"/>	X <input type="text"/>	= <input type="text"/>
Independent Claims	<input type="text"/>	- 3** =	<input type="text"/>	X <input type="text"/>	= <input type="text"/>
Multiple Dependent				<input type="text"/>	= <input type="text"/>

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim, if not paid
1204	84	2204	42	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	205.00
1252	410	2252	205	Extension for reply within second month	
1253	930	2253	465	Extension for reply within third month	
1254	1,450	2254	725	Extension for reply within fourth month	
1255	1,970	2255	985	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,300	2453	650	Petition to revive - unintentional	
1501	1,300	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(a)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37 CFR 1.129(b))	
1801	750	2801	375	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 205.00

SUBMITTED BY

(Complete if applicable)

Name (Print/Type) Aaron T. Hokamura Registration No. 51,810 Telephone 650-569-5100
Signature [Signature] Date January 27, 2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO
09/900,708	07/06/2001	Keith D. Allen	R-733	3959

7590

08/26/2002

DELTAGEN, INC.
1003 Hamilton Avenue
Menlo Park, CA 94025

EXAMINER

QIAN, CELINE X


ART UNIT

PAPER NUMBER

1636

DATE MAILED: 08/26/2002

Please find below and/or attached an Office communication concerning this application or proceeding.



Office Action Summary

Application No.

09/900,708

Applicant(s)

ALLEN, KEITH D.

Examiner

Celine Qian

Art Unit

1636

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133)
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on 30 July 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☐ Claim(s) 1-34 is/are pending in the application.
- 4a) Of the above claim(s) 11-16 and 29-34 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) 1-10 and 17-28 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 06 July 2001 is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____
- 4) ☐ Interview Summary (PTO-413) Paper No(s) _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____

Notice of References Cited

Application/Control No.

09/900,708

Applicant(s)/Patent Under
Reexamination
ALLEN, KEITH D.

Examiner

Celine Qian

Art Unit

1636

Page 1 of 2

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Wall, Transgenic livestock: Progress and prospects for the future, 1996, THERIOGENOLOGY, Vol. 45, pp. 57-68
	V	Sigmund, Viewpoint: Are studies in genetically altered mice out of control?, 2000, ARTERIOSCLER THROMB. VASC. BIOL., Vol. 20, pp. 1425-1429
	W	Bradley et al., Modifying the mouse: Design and desire, 1992, BIO/TECHNOLOGY, Vol. 10, pp. 534-539
	X	Mullins et al., Perspective series: Molecular medicine in genetically engineered animals, 1996, J. CLIN. INVEST., Vol. 97, pp. 1557-1559

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a))
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited

Application/Control No.

09/900,708

Applicant(s)/Patent Under
Reexamination
ALLEN, KEITH D.

Examiner

Celine Qian

Art Unit

1636

Page 2 of 2

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable. Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Campbell et al., Totipotency or multipotentiality of cultured cells: Applications and progress, 1997, THERIOGENOLOGY, Vol. 47, pp. 63-72
	V	Manes et al., Genomic structure and comparison of mouse tissue-specific alkaline phosphatase genes, 1990, GENOMICS, Vol. 8, pp. 541-554
	W	Mansour et al., Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes, 1988, NATURE, Vol. 336, pp. 348-352
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a))
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Art Unit: 1636

DETAILED ACTION

Claims 1-34 are pending in the application.

Election/Restrictions

Applicant's election with traverse of Group I in Paper No. 8 is acknowledged. The traversal is on the ground(s) that the inventions of different groups are related and would not require a separate search that is burdensome. This is not found persuasive because the inventions of Groups I-VII are patentably distinct for the reasons set forth of the record mailed on 7/30/02. A search of the subject matter of one invention would not be co-extensive with a search of the other invention, and therefore the search would be burdensome.

The requirement is still deemed proper and is therefore made FINAL.

Claims 11-16 and 29-34 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 8.

Accordingly, claims 1-10 and 17-28 are pending in the application.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 8-10 and 17-28 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled

Art Unit: 1636

in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is "undue." These factors include, but are not limited to: (a) the breadth of the claims; (b) the nature of the invention; (c) the state of the prior art; (d) the relative skill of those in the art; (e) the level of predictability in the art; (f) the amount of direction provided by the inventor; (g) the existence of working examples; and (h) whether the quantity of experimentation needed to make or use the invention based on the content of the disclosure is "undue" (MPEP 2164.01 (a)).

The nature of the invention is a transgenic non-human animal and a cell derived from said animal whose genome comprises a disruption in its endogenous intestinal alkaline phosphatase (IAP) gene, and said animal having decreased level or no IAP protein, or mutated IAP protein. The claims are further drawn to a method of making said transgenic non-human animal by homologous recombination. The specification teaches that a homozygous IAP knockout mouse exhibits the phenotype of nociceptive disorder, abnormal sensitivity to temperature, abnormal sensitivity to pain, activity disorder, and anxiety disorder (see pages 53-54).

The breadth of claims is very broad. In the instant case, the broadest claim (8) is drawn to a transgenic non-human animal containing a disrupted endogenous IAP gene. The claims encompass any transgenic non-human animal containing any type of mutation or disruption in

Art Unit: 1636

IAP gene regardless of the phenotype. In addition, claims 10 and 27 encompass the method of generating an IAP knockout animal using any type of recipient cell.

The amount of guidance and working example in the specification is limited. The specification does not provide an enabling disclosure to make said transgenic animal except an IAP knockout mouse. The specification also fails to teach how to use a transgenic animal with said genotype but without a particular phenotype for the disclosed utility. The phenotype of the knockout animal is the essential element that is required to practice the use of the invention (the claims must recite the phenotype). Without teaching from the specification, one skilled in the art would have to turn to prior art for guidance to make and use the transgenic animal as claimed.

State of the Art, Predictability or Unpredictability of the art, Amount of experimentation necessary and Skill level of the artisan: When considering the predictability of this invention, one has to remember that many of the phenotypes examined in transgenic and knockout models are influenced by the genetic background in which they are studied and the effect of allelic variation and the interaction between the allelic variants (pg. 1425, paragraph 1 in Sigmund, C.D. 2000. Arterioscler Thromb Vasc Biol. 20:1425-1429). The specification discloses the phenotype of a homozygous PDE7A knockout mouse. However, the claims encompass heterozygotes, but since heterozygotes have one functional allele, the heterozygotes would not be expected to have the same phenotype as the homozygotes. Thus, the phenotype of a heterozygous transgenic or knockout animal is unpredictable. Thus, the specification, in the instant case, is not enabling for transgenic and/or knock out animals that exhibit no phenotype or that exhibit transgene-dependent phenotypes other than that disclosed in the instant specification. In addition, the transgene expression and the physiological consequences of transgene products are not always

Art Unit: 1636

accurately predicted in transgenic mouse studies (pg.62, paragraph 1, lines 7-9 in Wall, R.J. 1996. Theriogenology 45:57-68). The particular genetic elements required for optimal expression varies from species to species. Our lack of understanding of essential genetic control elements makes it difficult to design transgenes with predictable behavior (Wall, 1996). Therefore, in the absence of specific guidance and working examples, the production of transgenic animals with the phenotypes disclosed in the instant application is unpredictable. Thus, the specification is only enabling for a homozygous IAP knockout mouse with disclosed phenotype.

The specification fails to provide an enabling disclosure for the generation of other species of transgenic animals besides mice having a disruption in the IAP gene because the guidance offered in the specification is limited to the generation of mice harboring such mutations and no teachings or guidance are offered with regard to how one would generate any other type of animal. Since homologous recombination is required for gene targeting methods such as employed in the instant invention, embryonic stem (ES) cell must be available to carry out the method. To date, there is no teaching from the art that homologous recombination in a somatic cell and subsequent introduction of said cell to a blastocyst would generate an offspring carrying said gene mutation. The specification does not teach such a method either. The only species in which the ES is available is the mouse (see e.g. Bradley et al., paragraph bridging pages 537-538). Campbell and Wilmut, 1997 acknowledge reports of ES-like cell lines in a number of species, but emphasize that as yet there are no reports of any cell lines which contribute to the germ line in any species other than the mouse (p.65). Likewise, Mullins et al. (1996, Clin. Invest. Vol 97, no. 7, 1557-1560) teach that "although to date chimeric animals have

Art Unit: 1636

been generated from several species including the pig, in no species other than the mouse has germline transmission of an ES cell been successfully demonstrated. This remains a major goal for the future and may well require the use of novel strategies which depart widely from the traditional methods used in the mouse" (p.1558, column 2, paragraph 1). Therefore, no knockout animals can be made for any species other than the mouse at the time of filing. As such, the invention while being enabled for a homozygous knockout mouse, generated by using ES cells, containing homozygous disruption for the IAP gene with disclosed phenotype, does not extend the predictability of the invention to other animal systems.

The specification discloses that the homozygous mutant mice display an increase in thermal sensitivity as demonstrated by decreased latency to lick their hindpaw during the hot plate test. However, the specification only provides such data for two pair of mice. Moreover, one pair of mice display very similar latency (24.68 vs 23.28) to hindpaw licking (see Table 1, last col., 5 and 6th cell). It appears that this phenotype is inconsistent between two pairs of wild type and knockout mice. It is also unclear whether the hot plate test indicates thermal sensitivity, pain sensitivity and/or nociceptive sensitivity. As such, whether the IAP knockout mice exhibit the claimed phenotype of nociceptive disorder, increased pain sensitivity and increased thermal sensitivity is unpredictable.

In view of the limited guidance in the specification and the unpredictability of the art, one skilled in the art would have to engage in undue amount of experimentation overcome the problems as discussed above. Therefore, the invention is not enabled as claimed.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-4, 9, 10 and 28 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Regarding claims 1-4 and 10, it is unclear how the target construct is arranged. In other words, is the first polynucleotide adjacent to the second polynucleotide or there is a selectable marker in between? Where is the screening marker located in the construct? In addition, it is also unclear whether the first and second polynucleotide is a contiguous sequence of the target gene or just portions of the target gene. Moreover, it is not clear what the word "providing" encompasses in claims 3 and 4. As such, it is unclear how the method of claim 3 differs from the method of claim 4.

Regarding claim 2, the term "screening marker" renders the claim indefinite because it is unclear what term encompasses. In other words, it is unclear how a "screening marker" differs from the "selection marker" recited in claim 1.

Regarding claims 9 and 28, the word "derived" renders the claim indefinite because the nature and number of derivative processes is unknown.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1636

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-8 and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mansour et al (1988, Nature, vol. 336, No. 24, 348-352), in view of Manes et al (1990, Genomics, vol.8: 541-554).

The claims are drawn to an IAP gene-targeting construct and a method of making said construct. The claims are further drawn to a cell comprising a disruption in an IAP, and a method of producing a transgenic mouse comprising a disruption in an IAP gene by homologous recombination using the target construct.

Mansour et al. teach a strategy for targeted disruption of the *hprt* and proto-oncogene *int-2* in mice embryonic stem cells and subsequent generation of knockout mice. Their teaching addresses the previous technical difficulty of obtaining embryonic stem cell carrying non-selectable, targeted gene mutation at loci of interest, and therefore provides a model which can be used to produce homozygous mutation of any gene, regardless of its function, if a cloned fragment of the gene is available (see page 348, second paragraph, line 1-3, third paragraph, line 1-5, and page 352, fourth paragraph, line 1-3). Mansour et al. further teach the generation of two targeting constructs, pRV9.1/TK and pINT-2-N/TK, each contains two sequences from *hprt* and

Art Unit: 1636

int-2 respectively, and a neo selection marker in between the two sequences (see page 350, figure 3). However, Mansour et al. do not teach how to make a magnesium-dependent phosphatase gene target construct and knockout mouse.

Manes et al. teach that alkaline phosphatases are highly ubiquitous enzymes present in most species from bacteria to man, and isozymes of tissue specific alkaline phosphatases share highly homologous organization with each other (see page 541, 1st col. lines 1-3, and 2nd col., lines 12-14). Manes et al. also teach that this family of genes represent a system suitable for approaching questions concerning the evolution of tissues specific genes and their restricted expression, the mechanisms underlying genetic polymorphism, as well as the progressive change in the catalytic properties and function of enzymes in the context of an isozyme family (page 551, 2nd col., 3rd paragraph, lines 1-2 through page 552, 1st col., lines 1-5). Manes et al. further teach the cloning of mouse IAP, EAP (tissue specific alkaline phosphatase isozyme family member) gene and provided genomic sequence of these genes (see Figure 1 and 3).

Based on the teaching of Manes et al. that alkaline phosphatase gene family represents a system suitable for studying the evolution of tissue specific genes and their restricted expression, it would have been obvious to one of ordinary skill in the art to knockout the tissues specific IAP to study its function. The ordinary artisan would have been motivated to knockout the expression of the IAP gene in a mouse to study the function of this gene in context of the alkaline phosphatase family, and understanding its structure function relationship in evolutionary process, as suggested by the teaching of Manes et al. The ordinary artisan would have had reasonable expectation of success for making such a knockout mouse because of the teachings of Mansour et al., who teach a general method of targeted gene disruption in mice based on

Art Unit: 1636

homologous recombination using a cloned fragment of a desired gene, and Manes et al., who teach the coding sequence of the mouse IAP gene. Therefore, the invention would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celine X Qian whose telephone number is 703-306-0283. The examiner can normally be reached on 9:00-5:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Remy Yucel can be reached on 703-305-1998. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Celine Qian, Ph.D.
August 26, 2002

DAVID GUZO
PRIMARY EXAMINER
